日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Author Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

作者更正:基于 DCAF1 的 PROTAC 具有针对临床验证靶点的活性,可克服内在和获得性降解剂耐药性。

Schröder, Martin; Renatus, Martin; Liang, Xiaoyou; Meili, Fabian; Zoller, Thomas; Ferrand, Sandrine; Gauter, Francois; Li, Xiaoyan; Sigoillot, Frederic; Gleim, Scott; Stachyra, Therese-Marie; Thomas, Jason R; Begue, Damien; Khoshouei, Maryam; Lefeuvre, Peggy; Andraos-Rey, Rita; Chung, BoYee; Ma, Renate; Pinch, Benika; Hofmann, Andreas; Schirle, Markus; Schmiedeberg, Niko; Imbach, Patricia; Gorses, Delphine; Calkins, Keith; Bauer-Probst, Beatrice; Maschlej, Magdalena; Niederst, Matt; Maher, Rob; Henault, Martin; Alford, John; Ahrne, Erik; Tordella, Luca; Hollingworth, Greg; Thomä, Nicolas H; Vulpetti, Anna; Radimerski, Thomas; Holzer, Philipp; Carbonneau, Seth; Thoma, Claudio R

Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field

在靶向蛋白降解领域,发现了一种新兴的连接酶靶点——DCAF1 的新型结合剂。

Vulpetti, Anna; Holzer, Philipp; Schmiedeberg, Niko; Imbach-Weese, Patricia; Pissot-Soldermann, Carole; Hollingworth, Gregory J; Radimerski, Thomas; Thoma, Claudio R; Stachyra, Therese-Marie; Wojtynek, Matthias; Maschlej, Magdalena; Chau, Suzanne; Schuffenhauer, Ansgar; Fernández, César; Schröder, Martin; Renatus, Martin

Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097

更正:一组独特的 p53 靶基因可预测对选择性 p53-HDM2 抑制剂 NVP-CGM097 的反应。

Jeay, Sébastien; Gaulis, Swann; Ferretti, Stéphane; Bitter, Hans; Ito, Moriko; Valat, Thérèse; Murakami, Masato; Ruetz, Stephan; Guthy, Daniel A; Rynn, Caroline; Jensen, Michael R; Wiesmann, Marion; Kallen, Joerg; Furet, Pascal; Gessier, François; Holzer, Philipp; Masuya, Keiichi; Würthner, Jens; Halilovic, Ensar; Hofmann, Francesco; Sellers, William R; Graus Porta, Diana

A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097

一组独特的p53靶基因预测了对选择性p53-HDM2抑制剂NVP-CGM097的反应

Jeay, Sébastien; Gaulis, Swann; Ferretti, Stéphane; Bitter, Hans; Ito, Moriko; Valat, Thérèse; Murakami, Masato; Ruetz, Stephan; Guthy, Daniel A; Rynn, Caroline; Jensen, Michael R; Wiesmann, Marion; Kallen, Joerg; Furet, Pascal; Gessier, François; Holzer, Philipp; Masuya, Keiichi; Würthner, Jens; Halilovic, Ensar; Hofmann, Francesco; Sellers, William R; Graus Porta, Diana

The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.

小分子特异性 EphB4 激酶抑制剂 NVP-BHG712 可抑制 VEGF 驱动的血管生成

Martiny-Baron Georg, Holzer Philipp, Billy Eric, Schnell Christian, Brueggen Joseph, Ferretti Mireille, Schmiedeberg Niko, Wood Jeanette M, Furet Pascal, Imbach Patricia